Who are Salbutamol pMDI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Salbutamol (Ventolin®), Ventoline® Evohaler® 100 µg/inhalation pMDI, Albuterol/salbutamol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/salbutamol-pmdi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Salbutamol pMDI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Salbutamol pMDI (Salbutamol pMDI) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Short-acting beta-2 adrenergic agonist (SABA). Area: Respiratory.

phase 3 Short-acting beta-2 adrenergic agonist (SABA) Beta-2 adrenergic receptor (ADRB2) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Salbutamol pMDI (Salbutamol pMDI) — AstraZeneca. Salbutamol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid bronchodilation and relief of airway obstruction.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Salbutamol pMDI TARGET	Salbutamol pMDI	AstraZeneca	phase 3	Short-acting beta-2 adrenergic agonist (SABA)	Beta-2 adrenergic receptor (ADRB2)
Salbutamol (Ventolin®)	Salbutamol (Ventolin®)	Khyber Teaching Hospital	marketed	Short-acting beta-2 adrenergic agonist (SABA)	Beta-2 adrenergic receptor (ADRB2)
Ventoline® Evohaler® 100 µg/inhalation pMDI	Ventoline® Evohaler® 100 µg/inhalation pMDI	Orion Corporation, Orion Pharma	marketed	Short-acting beta-2 adrenergic agonist (SABA)	Beta-2 adrenergic receptor
Albuterol/salbutamol	Albuterol/salbutamol	GlaxoSmithKline	marketed	Short-acting beta-2 adrenergic agonist (SABA)	Beta-2 adrenergic receptor (ADRB2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Short-acting beta-2 adrenergic agonist (SABA) class)

AstraZeneca · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Khyber Teaching Hospital · 1 drug in this class
Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salbutamol pMDI — Competitive Intelligence Brief. https://druglandscape.com/ci/salbutamol-pmdi. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab